99 related articles for article (PubMed ID: 23972964)
1. Bosentan for mild pulmonary vascular disease in ASD patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial.
Van De Bruaene A; Jansen K; De Meester P; Delcroix M; Voigt JU; Gabriels C; Moons P; Budts W
Int J Cardiol; 2013 Oct; 168(5):5081-2. PubMed ID: 23972964
[No Abstract] [Full Text] [Related]
2. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis.
Berger RM; Beghetti M; Galiè N; Gatzoulis MA; Granton J; Lauer A; Chiossi E; Landzberg M
Int J Cardiol; 2010 Oct; 144(3):373-8. PubMed ID: 19464064
[TBL] [Abstract][Full Text] [Related]
3. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
4. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report.
Hoetzenecker K; Ankersmit HJ; Bonderman D; Hoetzenecker W; Seitelberger R; Klepetko W; Lang IM
J Thorac Cardiovasc Surg; 2009 Mar; 137(3):760-1. PubMed ID: 19258107
[No Abstract] [Full Text] [Related]
5. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
6. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E
J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156
[No Abstract] [Full Text] [Related]
7. [Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
Ahmadi-Simab K; Lamprecht P; Hellmisch B; Gross WL
Z Rheumatol; 2004 Dec; 63(6):495-7. PubMed ID: 15605216
[No Abstract] [Full Text] [Related]
8. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
[TBL] [Abstract][Full Text] [Related]
9. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438
[No Abstract] [Full Text] [Related]
10. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
Mohamed WA; Ismail M
J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
Foley RJ; Metersky ML
Respiration; 2008; 75(2):211-4. PubMed ID: 16293957
[TBL] [Abstract][Full Text] [Related]
13. Congenital right pulmonary artery agenesis with atrial septal defect and pulmonary hypertension.
Orun UA; Yilmaz O; Bilici M; Karademir S; Uner C; Senocak F; Dogan V
Congenit Heart Dis; 2012; 7(3):E6-9. PubMed ID: 21801314
[TBL] [Abstract][Full Text] [Related]
14. New hope for patients with pulmonary hypertension: endothelin receptor antagonists: update for the clinical nurse specialist.
O'Malley P
Clin Nurse Spec; 2004; 18(5):232-4. PubMed ID: 15540063
[No Abstract] [Full Text] [Related]
15. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
16. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
17. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].
Castro G
Rev Port Cardiol; 2001 Nov; 20(11):1151-2. PubMed ID: 11826707
[No Abstract] [Full Text] [Related]
18. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of mild, but symptomatic pulmonary hypertension].
Reichenberger F; Seeger W; Nitschmann S
Internist (Berl); 2009 Mar; 50(3):374-6. PubMed ID: 19225745
[No Abstract] [Full Text] [Related]
20. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
